Combination Therapy In Dyslipidemia:
Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evalua...
Gespeichert in:
Format: | Elektronisch E-Book |
---|---|
Sprache: | English |
Veröffentlicht: |
Cham
Springer International Publishing
2015
|
Ausgabe: | 1st ed. 2015 |
Schlagworte: | |
Online-Zugang: | UBR01 URL des Erstveröffentlichers |
Zusammenfassung: | Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia |
Beschreibung: | Foreword -- Statins and bile acid resins - is there a place for such a combination? -- Statins and fibrates - should it be recommended? -- Statins and ezetimibe - doubts or bright future? -- Statins and niacin - the end of residual risk therapy? -- Statins and omega-3 fatty acids - what more do we need? -- Statins and CETP inhibitors - anacetrapib and evacetrapib - the last hope? -- Statins and mipomersen - the issue of tolerability? -- Statins and lomitapide - a suitable response for HoFH -- Statins and PCSK9 inhibitors - defining the correct patients -- Other possible drug combination for dyslipidaemia -- Statins and nutraceuticals/functional food - Could be they combined? -- Lipid lowering therapy and apheresis - indications and outcomes -- Combination of lipid lowering agents with antihypertensive drugs - a joint fight against the two most important risk factors? -- Not only dyslipidaemia therapy - the time for polypills -- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom? -- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance? -- Conclusions and Take Home Message |
Beschreibung: | 1 Online Ressource (VIII, 205 Seiten, 22 Illustrationen, 15 Illustrationen in Farbe) |
ISBN: | 9783319204338 |
DOI: | 10.1007/978-3-319-20433-8 |
Internformat
MARC
LEADER | 00000nmm a2200000zc 4500 | ||
---|---|---|---|
001 | BV046812693 | ||
003 | DE-604 | ||
005 | 00000000000000.0 | ||
007 | cr|uuu---uuuuu | ||
008 | 200717s2015 |||| o||u| ||||||eng d | ||
020 | |a 9783319204338 |9 978-3-319-20433-8 | ||
024 | 7 | |a 10.1007/978-3-319-20433-8 |2 doi | |
035 | |a (ZDB-2-SME)978-3-319-20433-8 | ||
035 | |a (OCoLC)1190923854 | ||
035 | |a (DE-599)BVBBV046812693 | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a eng | |
049 | |a DE-355 | ||
082 | 0 | |a 616.12 | |
245 | 1 | 0 | |a Combination Therapy In Dyslipidemia |c edited by Maciej Banach |
250 | |a 1st ed. 2015 | ||
264 | 1 | |a Cham |b Springer International Publishing |c 2015 | |
300 | |a 1 Online Ressource (VIII, 205 Seiten, 22 Illustrationen, 15 Illustrationen in Farbe) | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
500 | |a Foreword -- Statins and bile acid resins - is there a place for such a combination? -- Statins and fibrates - should it be recommended? -- Statins and ezetimibe - doubts or bright future? -- Statins and niacin - the end of residual risk therapy? -- Statins and omega-3 fatty acids - what more do we need? -- Statins and CETP inhibitors - anacetrapib and evacetrapib - the last hope? -- Statins and mipomersen - the issue of tolerability? -- Statins and lomitapide - a suitable response for HoFH -- Statins and PCSK9 inhibitors - defining the correct patients -- Other possible drug combination for dyslipidaemia -- Statins and nutraceuticals/functional food - Could be they combined? -- Lipid lowering therapy and apheresis - indications and outcomes -- Combination of lipid lowering agents with antihypertensive drugs - a joint fight against the two most important risk factors? -- Not only dyslipidaemia therapy - the time for polypills -- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom? -- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance? -- Conclusions and Take Home Message | ||
520 | |a Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia | ||
650 | 4 | |a Cardiology | |
650 | 4 | |a Pharmacotherapy | |
650 | 4 | |a Pharmacology | |
700 | 1 | |a Banach, Maciej |e Sonstige |4 oth | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783319204345 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783319204321 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783319367217 |
856 | 4 | 0 | |u https://doi.org/10.1007/978-3-319-20433-8 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
912 | |a ZDB-2-SME | ||
940 | 1 | |q ZDB-2-SME_2015 | |
999 | |a oai:aleph.bib-bvb.de:BVB01-032221212 | ||
966 | e | |u https://doi.org/10.1007/978-3-319-20433-8 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_2015 |x Verlag |3 Volltext |
Datensatz im Suchindex
_version_ | 1804181619456606208 |
---|---|
adam_txt | |
any_adam_object | |
any_adam_object_boolean | |
building | Verbundindex |
bvnumber | BV046812693 |
collection | ZDB-2-SME |
ctrlnum | (ZDB-2-SME)978-3-319-20433-8 (OCoLC)1190923854 (DE-599)BVBBV046812693 |
dewey-full | 616.12 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 616 - Diseases |
dewey-raw | 616.12 |
dewey-search | 616.12 |
dewey-sort | 3616.12 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
discipline_str_mv | Medizin |
doi_str_mv | 10.1007/978-3-319-20433-8 |
edition | 1st ed. 2015 |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04306nmm a2200445zc 4500</leader><controlfield tag="001">BV046812693</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">200717s2015 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783319204338</subfield><subfield code="9">978-3-319-20433-8</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-319-20433-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-319-20433-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1190923854</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046812693</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.12</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Combination Therapy In Dyslipidemia</subfield><subfield code="c">edited by Maciej Banach</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2015</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cham</subfield><subfield code="b">Springer International Publishing</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online Ressource (VIII, 205 Seiten, 22 Illustrationen, 15 Illustrationen in Farbe)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Foreword -- Statins and bile acid resins - is there a place for such a combination? -- Statins and fibrates - should it be recommended? -- Statins and ezetimibe - doubts or bright future? -- Statins and niacin - the end of residual risk therapy? -- Statins and omega-3 fatty acids - what more do we need? -- Statins and CETP inhibitors - anacetrapib and evacetrapib - the last hope? -- Statins and mipomersen - the issue of tolerability? -- Statins and lomitapide - a suitable response for HoFH -- Statins and PCSK9 inhibitors - defining the correct patients -- Other possible drug combination for dyslipidaemia -- Statins and nutraceuticals/functional food - Could be they combined? -- Lipid lowering therapy and apheresis - indications and outcomes -- Combination of lipid lowering agents with antihypertensive drugs - a joint fight against the two most important risk factors? -- Not only dyslipidaemia therapy - the time for polypills -- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom? -- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance? -- Conclusions and Take Home Message</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Banach, Maciej</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783319204345</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783319204321</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783319367217</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-319-20433-8</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_2015</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032221212</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-319-20433-8</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_2015</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
id | DE-604.BV046812693 |
illustrated | Not Illustrated |
index_date | 2024-07-03T14:59:18Z |
indexdate | 2024-07-10T08:54:32Z |
institution | BVB |
isbn | 9783319204338 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032221212 |
oclc_num | 1190923854 |
open_access_boolean | |
owner | DE-355 DE-BY-UBR |
owner_facet | DE-355 DE-BY-UBR |
physical | 1 Online Ressource (VIII, 205 Seiten, 22 Illustrationen, 15 Illustrationen in Farbe) |
psigel | ZDB-2-SME ZDB-2-SME_2015 ZDB-2-SME ZDB-2-SME_2015 |
publishDate | 2015 |
publishDateSearch | 2015 |
publishDateSort | 2015 |
publisher | Springer International Publishing |
record_format | marc |
spelling | Combination Therapy In Dyslipidemia edited by Maciej Banach 1st ed. 2015 Cham Springer International Publishing 2015 1 Online Ressource (VIII, 205 Seiten, 22 Illustrationen, 15 Illustrationen in Farbe) txt rdacontent c rdamedia cr rdacarrier Foreword -- Statins and bile acid resins - is there a place for such a combination? -- Statins and fibrates - should it be recommended? -- Statins and ezetimibe - doubts or bright future? -- Statins and niacin - the end of residual risk therapy? -- Statins and omega-3 fatty acids - what more do we need? -- Statins and CETP inhibitors - anacetrapib and evacetrapib - the last hope? -- Statins and mipomersen - the issue of tolerability? -- Statins and lomitapide - a suitable response for HoFH -- Statins and PCSK9 inhibitors - defining the correct patients -- Other possible drug combination for dyslipidaemia -- Statins and nutraceuticals/functional food - Could be they combined? -- Lipid lowering therapy and apheresis - indications and outcomes -- Combination of lipid lowering agents with antihypertensive drugs - a joint fight against the two most important risk factors? -- Not only dyslipidaemia therapy - the time for polypills -- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom? -- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance? -- Conclusions and Take Home Message Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia Cardiology Pharmacotherapy Pharmacology Banach, Maciej Sonstige oth Erscheint auch als Druck-Ausgabe 9783319204345 Erscheint auch als Druck-Ausgabe 9783319204321 Erscheint auch als Druck-Ausgabe 9783319367217 https://doi.org/10.1007/978-3-319-20433-8 Verlag URL des Erstveröffentlichers Volltext |
spellingShingle | Combination Therapy In Dyslipidemia Cardiology Pharmacotherapy Pharmacology |
title | Combination Therapy In Dyslipidemia |
title_auth | Combination Therapy In Dyslipidemia |
title_exact_search | Combination Therapy In Dyslipidemia |
title_exact_search_txtP | Combination Therapy In Dyslipidemia |
title_full | Combination Therapy In Dyslipidemia edited by Maciej Banach |
title_fullStr | Combination Therapy In Dyslipidemia edited by Maciej Banach |
title_full_unstemmed | Combination Therapy In Dyslipidemia edited by Maciej Banach |
title_short | Combination Therapy In Dyslipidemia |
title_sort | combination therapy in dyslipidemia |
topic | Cardiology Pharmacotherapy Pharmacology |
topic_facet | Cardiology Pharmacotherapy Pharmacology |
url | https://doi.org/10.1007/978-3-319-20433-8 |
work_keys_str_mv | AT banachmaciej combinationtherapyindyslipidemia |